Loading...
•
Sep 30, 2021
Esperion Q3 2021 Earnings Report
Esperion's Q3 2021 financial results were reported, highlighting strategic adjustments and progress in clinical trials.
Key Takeaways
Esperion reported U.S. net product revenue of $10.9 million for Q3 2021. The company is focusing on aligning its operational and expense structure for long-term growth, with the CLEAR Outcomes study on track for MACE accumulation in 2H 2022.
Announced strategic plan to align operational and expense structure.
Achieved 80% MACE accumulation in the CLEAR Outcomes Trial in October.
Continued European rollout of NILEMDO® and NUSTENDI® with partner Daiichi Sankyo.
Entered into an agreement to exchange $15 million of convertible notes for common stock.
Esperion
Esperion
Esperion Revenue by Segment
Revenue by Segment
U.S. Net Product Revenue
CapyFin.comCollaboration Revenue
CapyFin.com Forward Guidance
Esperion anticipates Research and Development expenses for fiscal year 2022 to be $100 to $110 million and Selling, General and Administrative expenses for fiscal year 2022 to be $120 to $130 million. Esperion expects fiscal year 2022 operating expenses to be $220 to $240 million, inclusive of $25 million of non-cash, stock-based compensation expense.
Positive Outlook
- Research and Development expenses for the full year 2021 are expected to be $110 million to $115 million.
- Selling, General and Administrative expenses for the full year 2021 are expected to be $195 million to $200 million.
- Esperion expects full-year 2021 operating expenses to be approximately $305 million to $315 million, inclusive of $25 million of non-cash, stock-based compensation.
- Research and Development expenses for fiscal year 2022 to be $100 to $110 million
- Selling, General and Administrative expenses for fiscal year 2022 to be $120 to $130 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income